Breaking News
Get 60% Off 0
Cyber Monday Deal: Up to 60% off InvestingPro
CLAIM SALE
Close

Phaxiam Therapeutics SA (0QSS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.60 +1.60    +0.00%
27/11 - Closed. Currency in EUR
  • Volume: 30
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 1.60 - 1.60
Type:  Equity
Market:  United Kingdom
ISIN:  FR001400K4B1 
SEDOL:  BRF1RB6
Phaxiam Therapeutics 1.60 +1.60 +0.00%

Phaxiam Therapeutics Company Profile

 
Read the Phaxiam Therapeutics company profile to learn more about the business and the management team. View Phaxiam Therapeutics SA facts about how many employees Phaxiam Therapeutics has, PHXM company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

45

Equity Type

DRC

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Contact Information

Address 60 Avenue Rockefeller Bâtiment Adénine
Lyon, 69008
France
Phone 33 4 78 74 44 38
Fax 33 4 78 75 56 29

Top Executives

Name Age Since Title
Philippe Archinard 64 2013 Independent Director
Hilde Windels 58 2014 Independent Director
Gil Beyen 61 2013 Vice Chairman
Didier Hoch - 2023 Chairman of the Board
Leila Nicolas 44 2023 Representative Director
Robert Sebbag - 2023 Independent Director
Valerie Faillat - 2024 Independent Director
Guy Rigaud 77 2023 Board Censor
Eric Raymond - 2009 Consultant & Member of Scientific Board
Philip L. Lorenzi - 2010 Consultant & Member of Scientific Board
Bridget Bax - 2012 Consultant & Member of Scientific Board
Arthur E. Frankel - 2012 Consultant & Member of Scientific Board
Kurt C. Gunter 69 2012 Consultant & Member of Scientific Board
Olivier Martinez 51 2024 Board Censor
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Phaxiam Therapeutics (PHXM) Price Discussion

Write your thoughts about Phaxiam Therapeutics SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email